UBS Group
ATTO

UBS Group’s Attovia Therapeutics ATTO Stock Holding History

UBS Group’s Portfolio ATTO Stock Details ATTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.15M Buy
+183,751
New +$3.87M ﹤0.01% 4574

Other funds holding ATTO

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group's ATTO Position: Q3 2026 in Review

UBS Group opened a new position in Attovia Therapeutics (ATTO) in Q3 2026: 183,751 shares worth $3.15M. The stake represents ﹤0.01% of the portfolio and ranks #4574 among its holdings.

27 funds tracked by Wall St. Rank hold ATTO as of Q3 2026.

  • UBS Group held 183,751 shares of Attovia Therapeutics worth $3.15M as of Q3 2026.
  • Attovia Therapeutics was a new UBS Group position in Q3 2026.
  • Attovia Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4574 holding.
  • 27 funds tracked by Wall St. Rank held Attovia Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.